Key Takeaways
- • Brevan Howard allocates $200 million to Catalio Capital Management's healthcare-focused public equities fund via a separately managed account structure, enabling real-time risk monitoring while delegating stock selection to specialist managers.
- • Catalio Capital has delivered a 49% net return since its 2023 launch and 12% net year-to-date performance through October 31, 2025, managing $2.3 billion in assets across public and private healthcare investments including pharmaceuticals, medical devices, diagnostics, and data companies.
- • The investment reflects a structural industry shift: Goldman Sachs data shows multi-manager hedge funds investing in external funds surged from just over 50% in 2022 to nearly 75% by October 2025, signaling broader adoption of specialist alpha strategies.
- • Catalio's leadership includes co-founders George Petrocheilos and Jacob Vogelstein, portfolio manager Ben Snedeker (formerly of D.E. Shaw), and backing from major institutional investor KKR, establishing credibility within the macro hedge fund ecosystem.
- • The separately managed account structure provides Brevan Howard contractual oversight and exit optionality compared to traditional fund vehicles, addressing institutional investors' preference for transparency and liquidity control in sub-advised strategies.
Summary
Brevan Howard, the London-based macro hedge fund, has committed $200 million to Catalio Capital Management's healthcare-focused public equities fund, marking a high-profile example of large multi-manager funds outsourcing specialized stock selection. Rather than deploying capital into a traditional locked-up fund structure, Brevan Howard has negotiated a separately managed account arrangement that preserves its risk management authority while ceding trading discretion to Catalio's dedicated healthcare expertise.
Catalio Capital, co-founded by George Petrocheilos and Jacob Vogelstein, has built a compelling track record to justify the capital allocation. Since inception in 2023, the firm has posted a 49% net return, with year-to-date performance through October 31, 2025, reaching 12% net. The fund currently manages $2.3 billion in assets across both public and private equity positions spanning pharmaceuticals, medical devices, diagnostics, and healthcare data companies. The management team includes Ben Snedeker, a former portfolio manager at D.E. Shaw, and counts KKR among its institutional backers—credentials that enhance its standing within the macro hedge fund community.
The separately managed account structure is strategically significant for Brevan Howard. Rather than committing capital blind to a pooled vehicle, the arrangement grants Brevan real-time visibility into Catalio's portfolio positions, allows continuous monitoring of risk exposure, and preserves the option to terminate the relationship faster than would be possible with a traditional fund lock-up. This structure reflects institutional preferences for transparency and liquidity optionality in sub-advised strategies.
Brevan Howard's investment exemplifies a broader industry reshaping underway in hedge fund capital allocation. According to Goldman Sachs, the proportion of multi-manager hedge funds deploying capital into external specialist funds surged from just over 50% in 2022 to nearly 75% by October 2025. This trend indicates that large macro funds increasingly recognize the value of outsourcing thematic or sector-specific equity selection to dedicated managers rather than maintaining these capabilities in-house. Healthcare, with its complex regulatory environment, scientific nuances, and data-driven fundamentals, has emerged as a prime domain for this specialist alpha model. The Brevan Howard-Catalio partnership thus reflects both a vote of confidence in Catalio's execution and validation of the multi-manager hedge fund industry's structural evolution toward specialized external capital deployment.
Catalio Capital, co-founded by George Petrocheilos and Jacob Vogelstein, has built a compelling track record to justify the capital allocation. Since inception in 2023, the firm has posted a 49% net return, with year-to-date performance through October 31, 2025, reaching 12% net. The fund currently manages $2.3 billion in assets across both public and private equity positions spanning pharmaceuticals, medical devices, diagnostics, and healthcare data companies. The management team includes Ben Snedeker, a former portfolio manager at D.E. Shaw, and counts KKR among its institutional backers—credentials that enhance its standing within the macro hedge fund community.
The separately managed account structure is strategically significant for Brevan Howard. Rather than committing capital blind to a pooled vehicle, the arrangement grants Brevan real-time visibility into Catalio's portfolio positions, allows continuous monitoring of risk exposure, and preserves the option to terminate the relationship faster than would be possible with a traditional fund lock-up. This structure reflects institutional preferences for transparency and liquidity optionality in sub-advised strategies.
Brevan Howard's investment exemplifies a broader industry reshaping underway in hedge fund capital allocation. According to Goldman Sachs, the proportion of multi-manager hedge funds deploying capital into external specialist funds surged from just over 50% in 2022 to nearly 75% by October 2025. This trend indicates that large macro funds increasingly recognize the value of outsourcing thematic or sector-specific equity selection to dedicated managers rather than maintaining these capabilities in-house. Healthcare, with its complex regulatory environment, scientific nuances, and data-driven fundamentals, has emerged as a prime domain for this specialist alpha model. The Brevan Howard-Catalio partnership thus reflects both a vote of confidence in Catalio's execution and validation of the multi-manager hedge fund industry's structural evolution toward specialized external capital deployment.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.